Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
5 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunoblastic morphology as a possible prognostic indicator for the outcome of the patients with diffuse large B cell lymphoma in era of the rituximab based treatment: single centre experience(Medip Academy, 2013-05); ; ; ; Dukovski, DushkoRecently the results from one large prospective study indicated that immunoblastic morphology and not immunohistohemical features predict the outcome of the Diffuse large B lymphoma (DLBL). In order to investigate the prediction value of the immunoblastic morphology (IB) as a possible prognostic indicator for the outcome of our DLBL patient treated with the Rituximab (R)-CHOP regimen we conducted a retrospective study. Our study enrolled 192 DLBL patients diagnosed and treated at the University Clinic of Hematology in the period between February 2002 and December 2007. They were all treated with R-CHOP regimen and the median follow-up of the patient was 36 months. We analyzed the biopsy samples immunohistochemically for markers of germinal center (BCL6), postgerminal center (MUM1) and apoptosis (BCL2).The patients were categorized as DLBL(132; 68.7%), IB(60; 31.2). The median overall survival time (OS) were 59.3 months in DLBL group and 42.2 months in IB group, and time to treatment (TT) were 56.8 and 30.6 months respectively for the IB group. The DLBL and IB groups were comparable regarding the age, gender distributions and all others already established prognostic parameters as performance status, advanced IPI, albumin level except for the low IPI 0-2 which was statistically associated with the DLBL group (p=.024). Our results did not show any statistical survival advantage and better outcome for the patient classified as DLBL when treated with R-CHOP and indicate that immunohistohemical markers do not really reflect the molecular diversity of the tumor. Our work shows that IB morphology is a major risk factor in DLBL patients treated with RCHOP. Therefore this morphology appears to capture some adverse molecular events that a currently hard to detect with routine diagnostic procedures. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic impact of immunophenotyping of diffuse large B-cell lymphoma - a single-centre experience(Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, 2021-07); ; ; ; The concept generated by biological expression profile divided patients with diffuse large B-cell lymphoma (DLBCL) into two subtypes. This concept has been presented in the recent editions of WHO classification and became a prognostic tool. Aim of the study was introduction of new three-marker model for immunohistochemical and prognostic subclasification of patients with DLBCL. Our retrospective study enrolled 200 adult patients with DLBCL diagnosed and treated in the period between January 2013 to January 2021. They were all treated with chemoimmunotherapy with R+/-CHOP regimen and the median follow-up of the patients was 48 months. We analysed the biopsy samples immunohistochemically with the markers of germinal (BCL6) and post-germinal centre (MUM1), and the marker of apoptosis (BCL2). Using the immunohistochemical three-marker model, which consisted of BCL-2, BCL-6, and MUM1, we distributed the patients with DLBCL into 2 subgroups: germinal centre – like (GCL) and activated centre-like lymphoma (ACL). The GCL and ACL patients were comparable regarding age, gender and all other already established prognostic parameters. Patients with GCL had overall survival of 140 months, and patients with ACL had overall survival of 88 months. ACL patients with BCL2 expression had a shorter survival compared to ACL patients without BCL2 expression. The difference in survival was statistically significant for p=0.01914. The study introduced the new three-marker model for immunohistochemical subclasification of patients with DLBCL treated with immunochemotherapy. Apoptotic marker BCL2 is a strong survival predictor. In the present study, we confirmed the prognostic importance of BCL2 protein expression, which showed a predictive capacity in ACL. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Rituximab maintenance therapy in diffuse large B-cell lymphoma: single center experience(European Hematology Association, 2013); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RITUXIMAB MAINTENANCE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA - SINGLE CENTAR EXPERIENCE(2013); ; ; Dusko Dukovski - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hypermutation of the gene in primary mediastinal lymphoma and other types of diffuse B cell lymphoma(2009); ; ;